Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products ... Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 15 development-stage ...

Royalty Pharma Plc’s (NASDAQ:RPRX) portfolio includes royalties in over 35 commercial products ... Pfizer’s Nurtec ODT, and others. The company delivered $2.8 billion in Portfolio Receipts ...

Nurtec ODT (rimegepant) is a prescription drug that treats and helps prevent migraine episodes. It works by blocking a certain protein in the brain and nervous system that can cause migraine.

The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

Pfizer PFE0.34%increase; green up pointing triangle had a problem. Doctors weren’t prescribing its migraine drug Nurtec because they assumed insurance coverage would be too much of a hassle.

Find out the winners of each category… Join us as we honor the biggest, boldest and most creative real estate deals done… Don't miss the 2025 Commercial Real Estate Developers Power Breakfast ...

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on ...

However, the private education sector has transformed into a ruthless commercial enterprise, prioritising financial gains over intellectual nourishment. Often referred to as the Private Education ...